Topics

FDA Grants Breakthrough Therapy Designation to Niraparib for mCRPC

20:00 EDT 3 Oct 2019 | Cancer Networks

The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.

Original Article: FDA Grants Breakthrough Therapy Designation to Niraparib for mCRPC

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to Niraparib for mCRPC"

Quick Search

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...